Business Wire

Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week ...

Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile ...
Finanznachrichten

Ferring Pharmaceuticals: Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at ...

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for ...